Marcela V. Maus Sells 3,900 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

2seventy bio, Inc. (NASDAQ:TSVT) Director Marcela V. Maus sold 3,900 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $3.38, for a total transaction of $13,182.00. Following the completion of the transaction, the director now directly owns 23,752 shares in the company, valued at approximately $80,281.76. The trade was a 14.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

2seventy bio Price Performance

Shares of 2seventy bio stock opened at $3.23 on Friday. The stock has a market cap of $166.64 million, a price-to-earnings ratio of -1.69 and a beta of 1.78. The firm’s 50-day moving average is $4.64 and its two-hundred day moving average is $4.46. 2seventy bio, Inc. has a 1 year low of $1.67 and a 1 year high of $6.40.

Institutional Trading of 2seventy bio

Several hedge funds have recently modified their holdings of the company. Erste Asset Management GmbH purchased a new position in shares of 2seventy bio in the 3rd quarter valued at approximately $25,000. Readystate Asset Management LP purchased a new position in 2seventy bio during the 3rd quarter worth approximately $53,000. SkyView Investment Advisors LLC raised its position in 2seventy bio by 25.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after buying an additional 2,500 shares during the last quarter. GSA Capital Partners LLP purchased a new position in 2seventy bio during the 3rd quarter worth approximately $64,000. Finally, Nisa Investment Advisors LLC purchased a new position in 2seventy bio during the 2nd quarter worth approximately $52,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley decreased their price target on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.